X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FRESENIUS KABI ONCO. AJANTA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 21.7 22.1 98.1% View Chart
P/BV x 9.4 3.1 301.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AJANTA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,720176 977.3%   
Low Rs1,10379 1,405.1%   
Sales per share (Unadj.) Rs194.637.7 516.4%  
Earnings per share (Unadj.) Rs45.25.1 887.8%  
Cash flow per share (Unadj.) Rs50.36.7 748.1%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.042.5 310.3%  
Shares outstanding (eoy) m88.77158.23 56.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.4 214.8%   
Avg P/E ratio x31.225.0 124.9%  
P/CF ratio (eoy) x28.118.9 148.3%  
Price / Book Value ratio x10.73.0 357.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,29920,135 622.3%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,570703 365.5%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m17,2755,963 289.7%  
Other income Rs m16618 923.9%   
Total revenues Rs m17,4425,981 291.6%   
Gross profit Rs m5,8071,430 406.1%  
Depreciation Rs m451258 174.7%   
Interest Rs m49-26 -188.1%   
Profit before tax Rs m5,4741,216 450.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,460342 426.6%   
Profit after tax Rs m4,014806 498.1%  
Gross profit margin %33.624.0 140.2%  
Effective tax rate %26.728.1 94.8%   
Net profit margin %23.213.5 171.9%  
BALANCE SHEET DATA
Current assets Rs m7,6395,102 149.7%   
Current liabilities Rs m2,7152,385 113.8%   
Net working cap to sales %28.545.6 62.6%  
Current ratio x2.82.1 131.6%  
Inventory Days Days43150 28.8%  
Debtors Days Days79113 69.4%  
Net fixed assets Rs m6,9145,148 134.3%   
Share capital Rs m177158 111.8%   
"Free" reserves Rs m11,4426,556 174.5%   
Net worth Rs m11,7216,732 174.1%   
Long term debt Rs m149952 15.6%   
Total assets Rs m14,81410,388 142.6%  
Interest coverage x112.9-45.8 -246.7%   
Debt to equity ratio x00.1 9.0%  
Sales to assets ratio x1.20.6 203.1%   
Return on assets %27.47.5 365.3%  
Return on equity %34.212.0 286.1%  
Return on capital %46.514.6 318.6%  
Exports to sales %55.174.5 74.1%   
Imports to sales %6.024.8 24.2%   
Exports (fob) Rs m9,5274,441 214.5%   
Imports (cif) Rs m1,0381,477 70.2%   
Fx inflow Rs m10,4225,298 196.7%   
Fx outflow Rs m1,6781,772 94.7%   
Net fx Rs m8,7443,525 248.0%   
CASH FLOW
From Operations Rs m3,2641,274 256.2%  
From Investments Rs m-2,093-1,204 173.8%  
From Financial Activity Rs m-1,186-196 604.6%  
Net Cashflow Rs m-15-126 11.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 9.6 79.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 42,599 49.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   CIPLA  PFIZER  NATCO PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS